Cerenome (PSTV) FCF Margin (2011 - 2026)
Plus Therapeutics (PSTV) posted quarterly FCF Margin of 686.38% for Q1 2026, down 10328.0% year-over-year from N/an in Q1 2025, and down 48.82% quarter-over-quarter from 461.23% in Q4 2025.
Cerenome (PSTV) FCF Margin (2011 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported FCF Margin for 14 consecutive years, with 686.38% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin fell 10328.0% year-over-year to 686.38%; the TTM figure through Mar 2026 stood at 419.2% (down 18251.0% YoY), while the FY2025 annual figure was 399.81%, down 21609.0% from the prior year.
- FCF Margin slipped to 686.38% in Q1 2026 per PSTV's latest filing, from 461.23% in the prior quarter.
- Across five years, FCF Margin topped out at 48.29% in Q4 2023 and bottomed at 4427.4% in Q3 2022.
- Historically, FCF Margin has averaged 871.16% across 5 years, with a median of 271.5% in 2024.
- Annual changes were most pronounced in 2023 — FCF Margin jumped 423312 bps — and 2025, when it sank 37469 bps.
- Plus Therapeutics' FCF Margin stood at 4129.92% in 2022, then jumped by 101 bps to 48.29% in 2023, then slumped by 279 bps to 86.54% in 2024, then slumped by 433 bps to 461.23% in 2025, then sank by 49 bps to 686.38% in 2026.
- Business Quant data shows PSTV's FCF Margin at 686.38% in Q1 2026, 461.23% in Q4 2025, and 183.04% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 70.82% |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | -1,856.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -686.38% |
| Dec 31, 2025 | -461.23% |
| Sep 30, 2025 | -183.04% |
| Jun 30, 2025 | -417.63% |
| Mar 31, 2025 | -583.10% |
| Dec 31, 2024 | -86.54% |
| Sep 30, 2024 | -253.71% |
| Jun 30, 2024 | -96.25% |
| Mar 31, 2024 | -271.50% |
| Dec 31, 2023 | 48.29% |
| Sep 30, 2023 | -194.27% |
| Jun 30, 2023 | -146.79% |
| Mar 31, 2023 | -1,178.00% |
| Dec 31, 2022 | -4,129.92% |
| Sep 30, 2022 | -4,427.40% |
| Mar 31, 2019 | -466.00% |
| Dec 31, 2018 | -175.32% |
| Sep 30, 2018 | -314.34% |
| Jun 30, 2018 | -416.06% |
| Mar 31, 2018 | -570.73% |